EICHOR
● Recruiting
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
Condition: End Stage Renal Disease · Sponsor: Houssam Farres, M.D.
About this study
Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.
This description comes directly from the study's public registry record.
Talk to the study team
Reagan Dukes · (904) 953-2077 · Dukes.Reagan@mayo.edu
Mauricia Buchanan · (904) 953-2077 · buchanan.mauricia@mayo.edu
Always discuss trial participation with your own doctor first.
Locations (1)
| Mayo Clinic in Florida | Jacksonville, Florida, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04392206